Evidence map›Paper›PMID 36689040›Full record

ReviewMolecular and cellular biochemistry2023

Solanum nigrum L. in COVID-19 and post-COVID complications: a propitious candidate.

Divya Sharma, Mit Joshi, Subbu Apparsundaram, Ramesh K Goyal, Bhoomika Patel, Mahaveer Dhobi

Open access · bronzeAbstract readReview
In one paragraph

Review in Molecular and cellular biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Divya SharmaDelhi Pharmaceutical Sciences and Research University, 110017, New Delhi, India.
Mit JoshiInstitute of Pharmacy, Nirma University, 382481, Ahmedabad, Gujarat, India.
Subbu ApparsundaramDelhi Pharmaceutical Sciences and Research University, 110017, New Delhi, India.
Ramesh K GoyalDelhi Pharmaceutical Sciences and Research University, 110017, New Delhi, India.
Bhoomika PatelNational Forensic Sciences University, Sector-9, Gandhinagar-382007, Gujarat, India. drbhoomikampatel@gmail.com.
Mahaveer DhobiDelhi Pharmaceutical Sciences and Research University, 110017, New Delhi, India. mahaveer.pharma@gmail.com.
Delhi Pharmaceutical Science and Research University · INNational Forensic Sciences University · INNirma University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is caused by severe acute respiratory syndrome coronavirus-2, SARS-CoV-2. COVID-19 has changed the world scenario and caused mortality around the globe. Patients who recovered from COVID-19 have shown neurological, psychological, renal, cardiovascular, pulmonary, and hematological complications. In some patients, complications lasted more than 6 months. However, significantly less attention has been given to post-COVID complications. Currently available drugs are used to tackle the complications, but new interventions must address the problem. Phytochemicals from natural sources have been evaluated in recent times to cure or alleviate COVID-19 symptoms. An edible plant, Solanum nigrum, could be therapeutic in treating COVID-19 as the AYUSH ministry of India prescribes it during the pandemic. S. nigrum demonstrates anti-inflammatory, immunomodulatory, and antiviral action to treat the SARS-CoV-2 infection and its post-complications. Different parts of the plant represent a reduction in proinflammatory cytokines and prevent multi-organ failure by protecting various organs (liver, kidney, heart, neuro, and lung). The review proposes the possible role of the plant S. nigrum in managing the symptoms of COVID-19 and its post-COVID complications based on in silico docking and pharmacological studies. Further systematic and experimental studies are required to validate our hypothesis.

Indexed as

COVID-19Solanum nigrumAntiviral AgentsHumansLungSARS-CoV-2Antiviral AgentsCOVID-19Post-COVID complicationsSARS-CoV-2 PhytochemicalsSolanum nigrum

Identifiers

PMID36689040
PMCPMC9868520
OpenAlexW4317722120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.